12:00 AM
 | 
Feb 05, 2007
 |  BioCentury  |  Tools & Techniques

PTP-1B gatekeeper

While protein tyrosine phosphatase 1B acts as a gatekeeper molecule at the confluence of multiple signal transduction pathways, the enzyme so far has been targeted only for Type II diabetes and obesity. A paper published last week in Nature Genetics revealed another role for PTP-1B inhibitors, this time in suppressing HER2-positive breast cancer growth and metastasis.

PTP-1B inhibition has been shown to increase insulin sensitivity and improve glucose tolerance by preventing the enzyme from dephosphorylating the insulin receptor kinase. Based on that activity, several companies have PTP-1B inhibitors in development for diabetes and obesity.

"We found that the role of PTP-1B in modulating metabolism is also important for tumor development and metastasis," Michel Tremblay, director of the McGill Center for Cancer Research and co-author of the study, told BioCentury.

The researchers used a PTP-1B inhibitor to treat...

Read the full 667 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >